Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • S168: ERYTHROPOIETIN STIMULATI...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
S168: ERYTHROPOIETIN STIMULATION AGENTS SIGNIFICANTLY IMPROVES OUTCOME IN LOWER RISK MDS.

S168: ERYTHROPOIETIN STIMULATION AGENTS SIGNIFICANTLY IMPROVES OUTCOME IN LOWER RISK MDS.

Bibliographic Details
Main Authors: H. Garelius, A. Smith, T. Bagguley, A. Taylor, P. Fenaux, D. Bowen, A. Symeonidis, M. Mittelmann, R. Stauder, J. Čermák, G. Sanz, S. Langemeijer, L. Malcovati, U. Germing, R. Itzykson, A. Guerci-Bresler, D. Culligan, I. Kotsianidis, K. Koinig Mag, C. van Marrewijk, S. Crouch, T. de Witte, E. Hellström-Lindberg
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000843564.40783.b4
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000843564.40783.b4

Similar Items

  • P731: SURVIVAL IN LOWER-RISK MDS PATIENTS FROM EUMDS REGISTRY BY TWO TRANSPLANT SELECTION CRITERIA - IMPLICATIONS FOR TRANSPLANT DECISION
    by: Aleksandar Savic, et al.
    Published: (2023-08-01)
  • Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
    by: Theo de Witte, et al.
    Published: (2020-09-01)
  • Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry
    by: Marlijn Hoeks, et al.
    Published: (2020-03-01)
  • Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes
    by: Raphael Itzykson, et al.
    Published: (2018-08-01)
  • Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes
    by: Louise de Swart, et al.
    Published: (2020-03-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs